Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Whole-Breast Versus Accelerated Partial Radiotherapy: 10-Year Results

Whole-Breast Versus Accelerated Partial Radiotherapy: 10-Year Results

Breast cancer surgeryfollowed by adjuvant, recurrence-reducing, partial breast irradiation (accelerated partial-breast irradiation, APBI) produced 10-year recurrence rates equal to whole-breast irradiation (WBI), according to Meattini and colleagues' follow-up study at the 2019 San Antonio Breast Cancer Symposium(Abstract GS4-06). Easier to deliver and tolerate, partial therapy may be acceptable in early breast cancer. Many patients undergo lumpectomy followed by radiotherapy . Lead author Dr. Icro Meattini of the University of Florence said: “Postoperative radiation remains the foundation of adjuvant breast treatment, significantly reducing regional cancer incidence.” Researchers have investigated whether partial irradiation prevents recurrence as effectively as whole-breast treatment.

Study Details

Meattini examined a randomized phase III clinical trial called the APBI IMRT studywith 10-year follow-up. Its 5-year results showed no recurrence or survival differences. It enrolled women older than 40, totaling 520 with stage I or II cancer. Between 2005-2013, randomization was 1:1 to APBI or WBI. APBI delivered in 5 daily fractions a total 30 Gy to the bed; WBI delivered over 25 days total 50 Gy, plus a 5-day 10 Gy bed boost. Arms were comparable in age, size, type, and endocrine therapy, with average 10-year follow-up. Most had hormone receptor-positive, HER2 -negative cancer and were over 50.

Key Findings

• At 10 years, recurrence was % 3.3 with APBI versus % 2.6 with WBI.

• At 10 years, overall survival was % 92.7 with APBI versus % 93.3 with WBI. Neither difference was significant. These reinforce promising 5-year findings and excellent control. Selected patients have similar outcomes regardless of partial or whole irradiation. Partial treatment causes fewer cosmetic changes but is more costly. It may reduce adverse effects, improve quality of life, and substantially shorten treatment. It exemplifies de-escalation in breast oncology and may be a relatively cost-effective, safe, effective optimal choice for many patients.

Sources

2019 San Antonio Breast Cancer Symposium, Abstract GS4-06

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Whole-Breast Versus Accelerated Partial Radiotherapy: 10-Year Results

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy